{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:59:20Z","timestamp":1790686760621,"version":"4.1.0"},"reference-count":102,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":27,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.amjmed.2026.07.049","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:39:18Z","timestamp":1787848758000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Guidelines for prevention and management of complications of injection drug use: A WikiGuidelines group consensus statement"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7025-8638","authenticated-orcid":false,"given":"Nathanial S","family":"Nolan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Sherbuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mira","family":"Maximos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Egbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Cappiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph David","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Bradford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Lahey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spencer","family":"Liebman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terence","family":"Wuerz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Dominguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinna","family":"Thakarar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Eckhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei Quin","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratish","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Kurz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Hopgood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elana","family":"Rosenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Traver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5825-7891","authenticated-orcid":false,"given":"Madeline","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Henderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako Wendy","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Hojman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd C.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael A.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven YC","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghav","family":"Tirupathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Bourassa-Blanchette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Eaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Sanctuaire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Trotzky-Sirr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simeon D","family":"Kimmel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily G.","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad","family":"Spellberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5620-7286","authenticated-orcid":false,"given":"Rachel","family":"Baden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjmed.2026.07.049_bib0001","series-title":"World Drug Report 2023","year":"2023"},{"issue":"1","key":"10.1016\/j.amjmed.2026.07.049_bib0002","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/cid\/ciac543","article-title":"Estimated number of people who inject drugs in the United States","volume":"76","author":"Bradley","year":"2023","journal-title":"Clin Infect Dis Publ Infect Dis Soc Am"},{"issue":"11","key":"10.1016\/j.amjmed.2026.07.049_bib0003","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0242165","article-title":"Population-based trends in hospitalizations due to injection drug use-related serious bacterial infections, Oregon, 2008 to 2018","volume":"15","author":"Capizzi","year":"2020","journal-title":"PloS One"},{"issue":"Suppl 5","key":"10.1016\/j.amjmed.2026.07.049_bib0004","doi-asserted-by":"crossref","first-page":"S451","DOI":"10.1093\/infdis\/jiaa012","article-title":"Trends in morbidity, mortality, and cost of hospitalizations associated with infectious disease sequelae of the opioid epidemic","volume":"222","author":"Coyle","year":"2020","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.amjmed.2026.07.049_bib0005","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/ADM.0000000000000928","article-title":"Trends in hospitalizations for serious infections among people with opioid use disorder in Ontario, Canada","volume":"16","author":"Gomes","year":"2022","journal-title":"J Addict Med"},{"issue":"12","key":"10.1016\/j.amjmed.2026.07.049_bib0006","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1136\/bmjqs-2015-004411","article-title":"SQUIRE 2.0 (Standards for QUality Improvement Reporting Excellence): revised publication guidelines from a detailed consensus process","volume":"25","author":"Ogrinc","year":"2016","journal-title":"BMJ Qual Saf"},{"issue":"3","key":"10.1016\/j.amjmed.2026.07.049_bib0007","article-title":"Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence","volume":"2010","author":"Mattick","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.amjmed.2026.07.049_bib0008","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"2014","author":"Mattick","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.amjmed.2026.07.049_bib0009","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1001\/jamainternmed.2018.1052","article-title":"Weekly and monthly subcutaneous buprenorphine depot formulations versus daily sublingual buprenorphine with naloxone for treatment of opioid use disorder: a randomized clinical trial","volume":"178","author":"Lofwall","year":"2018","journal-title":"JAMA Intern Med"},{"issue":"10173","key":"10.1016\/j.amjmed.2026.07.049_bib0010","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S0140-6736(18)32259-1","article-title":"Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"393","author":"Haight","year":"2019","journal-title":"Lancet L Engl"},{"key":"10.1016\/j.amjmed.2026.07.049_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102311","article-title":"Superiority and cost-effectiveness of monthly extended-release buprenorphine versus daily standard of care medication: a pragmatic, parallel-group, open-label, multicentre, randomised, controlled, phase 3 trial","volume":"66","author":"Marsden","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"9","key":"10.1016\/j.amjmed.2026.07.049_bib0012","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.34540","article-title":"Buprenorphine dose and time to discontinuation among patients with opioid use disorder in the era of fentanyl","volume":"6","author":"Chambers","year":"2023","journal-title":"Jama Netw Open"},{"issue":"3","key":"10.1016\/j.amjmed.2026.07.049_bib0013","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/ADM.0000000000001300","article-title":"Higher first 30-day dose of buprenorphine for opioid use disorder treatment is associated with decreased mortality","volume":"18","author":"Lei","year":"2024","journal-title":"J Addict Med"},{"issue":"3","key":"10.1016\/j.amjmed.2026.07.049_bib0014","article-title":"Methadone maintenance at different dosages for opioid dependence","volume":"2010","author":"Faggiano","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"issue":"10118","key":"10.1016\/j.amjmed.2026.07.049_bib0015","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial","volume":"391","author":"Lee","year":"2018","journal-title":"Lancet L Engl"},{"issue":"2","key":"10.1016\/j.amjmed.2026.07.049_bib0016","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa2020214","article-title":"Bupropion and naltrexone in methamphetamine use disorder","volume":"384","author":"Trivedi","year":"2021","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.amjmed.2026.07.049_bib0017","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1001\/archgenpsychiatry.2011.124","article-title":"Mirtazapine to reduce methamphetamine use: a randomized controlled trial","volume":"68","author":"Colfax","year":"2011","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.amjmed.2026.07.049_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2022.109295","article-title":"Mirtazapine for the treatment of amphetamine and methamphetamine use disorder: a systematic review and meta-analysis","volume":"232","author":"Naji","year":"2022","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"10.1016\/j.amjmed.2026.07.049_bib0019","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1001\/jamapsychiatry.2019.3655","article-title":"Effects of mirtazapine for methamphetamine use disorder among cisgender men and transgender women who have sex with men: a placebo-controlled randomized clinical trial","volume":"77","author":"Coffin","year":"2020","journal-title":"Jama Psychiatry"},{"key":"10.1016\/j.amjmed.2026.07.049_bib0020","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1001\/jamapsychiatry.2026.0159","article-title":"Mirtazapine for methamphetamine use disorder: a randomized clinical trial","volume":"83","author":"McKetin","year":"2026","journal-title":"Jama Psychiatry"},{"issue":"4","key":"10.1016\/j.amjmed.2026.07.049_bib0021","article-title":"Psychosocial and medication interventions to stop or reduce alcohol consumption during pregnancy","volume":"2024","author":"Minozzi","year":"2024","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.amjmed.2026.07.049_bib0022","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1001\/jamainternmed.2024.8586","article-title":"Hospital Addiction consultation service and opioid Use disorder treatment: the START randomized clinical trial","volume":"185","author":"Ober","year":"2025","journal-title":"JAMA Intern Med"},{"issue":"9","key":"10.1016\/j.amjmed.2026.07.049_bib0023","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1001\/jamainternmed.2024.3422","article-title":"Addiction consultation services for opioid use disorder treatment initiation and engagement: a randomized clinical trial","volume":"184","author":"McNeely","year":"2024","journal-title":"JAMA Intern Med"},{"issue":"2","key":"10.1016\/j.amjmed.2026.07.049_bib0024","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jtcvs.2021.10.048","article-title":"Multidisciplinary team approach to confront the challenge of drug use-associated infective endocarditis","volume":"166","author":"Paras","year":"2023","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"12","key":"10.1016\/j.amjmed.2026.07.049_bib0025","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1007\/s11606-019-05251-9","article-title":"Inpatient addiction medicine consultation and post-hospital substance use disorder treatment engagement: a propensity-matched analysis","volume":"34","author":"Englander","year":"2019","journal-title":"J Gen Intern Med"},{"issue":"1","key":"10.1016\/j.amjmed.2026.07.049_bib0026","doi-asserted-by":"crossref","first-page":"ofac688","DOI":"10.1093\/ofid\/ofac688","article-title":"Integrated infectious disease and substance use disorder care for the treatment of injection drug use-associated infections: a prospective cohort study with historical control","volume":"10","author":"Serota","year":"2023","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"10.1016\/j.amjmed.2026.07.049_bib0027","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.amjmed.2021.08.007","article-title":"Patient-directed discharges among persons who use drugs hospitalized with invasive Staphylococcus aureus infections: opportunities for improvement","volume":"135","author":"Appa","year":"2022","journal-title":"Am J Med"},{"issue":"5","key":"10.1016\/j.amjmed.2026.07.049_bib0028","doi-asserted-by":"crossref","first-page":"ofaf257","DOI":"10.1093\/ofid\/ofaf257","article-title":"Incidence, patient-directed discharge, readmission, and mortality among people hospitalized with injecting-related infection: a population-based linkage study","volume":"12","author":"Masters","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.amjmed.2026.07.049_bib0029","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jsat.2020.01.010","article-title":"Hospitalization outcomes of people who use drugs: one size does not fit all","volume":"112","author":"Merchant","year":"2020","journal-title":"J Subst Abuse Treat"},{"issue":"4","key":"10.1016\/j.amjmed.2026.07.049_bib0030","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/SAP.0000000000004310","article-title":"Patient-directed discharge in hand infection cases: interactions between intravenous drug use, socioeconomic factors, and subsequent readmissions","volume":"94","author":"Soroudi","year":"2025","journal-title":"Ann Plast Surg"},{"key":"10.1016\/j.amjmed.2026.07.049_bib0031","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2025.1431384","article-title":"Socioeconomic differences in discharge against medical advice and hospital admission among emergency department visits associated with substance use in the United States","volume":"13","author":"Mojtahedi","year":"2025","journal-title":"Front Public Health"},{"issue":"2","key":"10.1016\/j.amjmed.2026.07.049_bib0032","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/ADM.0000000000000725","article-title":"Medications for opioid use disorder associated with less against medical advice discharge among persons who inject drugs hospitalized with an invasive infection","volume":"15","author":"Nolan","year":"2021","journal-title":"J Addict Med"},{"issue":"1","key":"10.1016\/j.amjmed.2026.07.049_bib0033","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1177\/0018578720985439","article-title":"Initiation of Buprenorphine\/Naloxone on rates of discharge against medical advice","volume":"57","author":"Kays","year":"2022","journal-title":"Hosp Pharm"},{"key":"10.1016\/j.amjmed.2026.07.049_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.108343","article-title":"Risk of discharge against medical advice among hospital inpatients with a history of opioid agonist therapy in New South Wales, Australia: a cohort study and nested crossover-cohort analysis","volume":"217","author":"Lewer","year":"2020","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.amjmed.2026.07.049_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajmo.2025.100107","article-title":"Clinical impact of an expanded MOUD access initiative for patients hospitalized with infections from intravenous opioid use","volume":"14","author":"Keegan","year":"2025","journal-title":"Am J Med Open"},{"issue":"10","key":"10.1016\/j.amjmed.2026.07.049_bib0036","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1007\/s11606-023-08059-w","article-title":"Association of early opioid withdrawal treatment strategy and patient-directed discharge among hospitalized patients with opioid use disorder","volume":"38","author":"Alrawashdeh","year":"2023","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.amjmed.2026.07.049_bib0037","article-title":"I feel like they\u2019re actually listening to me\u201d: a pilot study of a hospital discharge decision-making conversation guide for patients with injection drug use-associated infections","volume":"10","author":"Thakarar","year":"2023","journal-title":"Ther Adv Infect Dis"},{"key":"10.1016\/j.amjmed.2026.07.049_bib0038","article-title":"I know my body better than anyone else\u201d: a qualitative study of perspectives of people with lived experience on antimicrobial treatment decisions for injection drug use-associated infections","volume":"10","author":"Eckland","year":"2023","journal-title":"Ther Adv Infect Dis"},{"issue":"6","key":"10.1016\/j.amjmed.2026.07.049_bib0039","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1093\/cid\/ciaf231","article-title":"Ethical management of challenging behaviors in hospitalized people who use drugs","volume":"80","author":"Yen","year":"2025","journal-title":"Clin Infect Dis Publ Infect Dis Soc Am"},{"issue":"1","key":"10.1016\/j.amjmed.2026.07.049_bib0040","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12954-025-01240-w","article-title":"\u201cIt\u2019s nothing personal\u201d: understanding barriers to relational harm reduction practices during inpatient hospitalization","volume":"22","author":"Leon","year":"2025","journal-title":"Harm Reduct J"},{"issue":"9","key":"10.1016\/j.amjmed.2026.07.049_bib0041","doi-asserted-by":"crossref","first-page":"ofy194","DOI":"10.1093\/ofid\/ofy194","article-title":"Outpatient parenteral antimicrobial therapy among people who inject drugs: a review of the literature","volume":"5","author":"Suzuki","year":"2018","journal-title":"Open Forum Infect Dis"},{"issue":"Suppl 5","key":"10.1016\/j.amjmed.2026.07.049_bib0042","doi-asserted-by":"crossref","first-page":"S494","DOI":"10.1093\/infdis\/jiaa025","article-title":"Feasibility and safety of outpatient parenteral antimicrobial therapy in conjunction with addiction treatment for people who inject drugs","volume":"222","author":"Price","year":"2020","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.amjmed.2026.07.049_bib0043","doi-asserted-by":"crossref","first-page":"ofy056","DOI":"10.1093\/ofid\/ofy056","article-title":"Outcomes according to discharge location for persons who inject drugs receiving outpatient parenteral antimicrobial therapy","volume":"5","author":"D\u2019Couto","year":"2018","journal-title":"Open Forum Infect Dis"},{"issue":"9","key":"10.1016\/j.amjmed.2026.07.049_bib0044","doi-asserted-by":"crossref","first-page":"e324","DOI":"10.1016\/j.amjmed.2022.02.021","article-title":"Peripherally inserted Central catheter line misuse among people who inject drugs while on therapy for infective endocarditis","volume":"135","author":"Adams","year":"2022","journal-title":"Am J Med"},{"issue":"7","key":"10.1016\/j.amjmed.2026.07.049_bib0045","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.26366","article-title":"Guidelines for diagnosis and management of infective endocarditis in adults: a WikiGuidelines group consensus statement","volume":"6","author":"McDonald","year":"2023","journal-title":"Jama Netw Open"},{"issue":"5","key":"10.1016\/j.amjmed.2026.07.049_bib0046","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.11321","article-title":"Use of novel strategies to develop guidelines for management of pyogenic osteomyelitis in adults: a WikiGuidelines group consensus statement","volume":"5","author":"Spellberg","year":"2022","journal-title":"Jama Netw Open"},{"key":"10.1016\/j.amjmed.2026.07.049_bib0047","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7573\/dic.212559","article-title":"Treatment of acute bacterial skin and skin structure infection with single-dose dalbavancin in persons who inject drugs","volume":"7","author":"Gonzalez","year":"2018","journal-title":"Drugs Context"},{"issue":"2","key":"10.1016\/j.amjmed.2026.07.049_bib0048","doi-asserted-by":"crossref","first-page":"ofz028","DOI":"10.1093\/ofid\/ofz028","article-title":"Dalbavancin as secondary therapy for serious Staphylococcus aureus infections in a vulnerable patient population","volume":"6","author":"Bryson-Cahn","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"4","key":"10.1016\/j.amjmed.2026.07.049_bib0049","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae186","article-title":"Real-world dalbavancin use for serious gram-positive infections: comparing outcomes between people who use and do not use drugs","volume":"11","author":"Zambrano","year":"2024","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"10.1016\/j.amjmed.2026.07.049_bib0050","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s40121-019-0247-0","article-title":"Dalbavancin use in vulnerable patients receiving outpatient parenteral antibiotic therapy for invasive gram-positive infections","volume":"8","author":"Bork","year":"2019","journal-title":"Infect Dis Ther"},{"issue":"10","key":"10.1016\/j.amjmed.2026.07.049_bib0051","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1001\/jama.2025.12543","article-title":"Dalbavancin for treatment of Staphylococcus aureus bacteremia: the DOTS randomized clinical trial","volume":"334","author":"Turner","year":"2025","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.amjmed.2026.07.049_bib0052","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.jacc.2020.11.062","article-title":"Prospective cohort study of infective endocarditis in people who inject drugs","volume":"77","author":"Peric\u00e0s","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.amjmed.2026.07.049_bib0053","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.jacc.2018.10.082","article-title":"Clinical outcomes of infective endocarditis in injection drug users","volume":"73","author":"Rudasill","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.amjmed.2026.07.049_bib0054","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.jtcvs.2016.02.072","article-title":"Surgical outcomes of infective endocarditis among intravenous drug users","volume":"152","author":"Kim","year":"2016","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"1","key":"10.1016\/j.amjmed.2026.07.049_bib0055","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1186\/s12879-019-4558-2","article-title":"Long term surgical outcomes for infective endocarditis in people who inject drugs: a systematic review and meta-analysis","volume":"19","author":"Goodman-Meza","year":"2019","journal-title":"BMC Infect Dis"},{"issue":"4","key":"10.1016\/j.amjmed.2026.07.049_bib0056","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s11606-021-07313-3","article-title":"Expanding the team: optimizing the multidisciplinary management of drug use-associated infective endocarditis","volume":"37","author":"O\u2019Donnell","year":"2022","journal-title":"J Gen Intern Med"},{"issue":"6","key":"10.1016\/j.amjmed.2026.07.049_bib0057","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.psym.2020.06.019","article-title":"Addiction management in hospitalized patients with intravenous drug use-associated infective endocarditis","volume":"61","author":"Ray","year":"2020","journal-title":"Psychosomatics"},{"issue":"3","key":"10.1016\/j.amjmed.2026.07.049_bib0058","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.athoracsur.2021.12.068","article-title":"Surgeons\u2019 Perspectives on valve surgery in people with drug use-associated infective endocarditis","volume":"116","author":"Wurcel","year":"2023","journal-title":"Ann Thorac Surg"},{"issue":"5","key":"10.1016\/j.amjmed.2026.07.049_bib0059","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.amepre.2021.04.017","article-title":"Supervised injection facilities as harm reduction: a systematic review","volume":"61","author":"Levengood","year":"2021","journal-title":"Am J Prev Med"},{"issue":"1","key":"10.1016\/j.amjmed.2026.07.049_bib0060","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1186\/s12889-025-22210-8","article-title":"Effectiveness of naloxone distribution in community settings to reduce opioid overdose deaths among people who use drugs: a systematic review and meta-analysis","volume":"25","author":"Fischer","year":"2025","journal-title":"BMC Public Health"},{"key":"10.1016\/j.amjmed.2026.07.049_bib0061","doi-asserted-by":"crossref","first-page":"j1550","DOI":"10.1136\/bmj.j1550","article-title":"Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ"},{"issue":"9775","key":"10.1016\/j.amjmed.2026.07.049_bib0062","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/S0140-6736(10)62353-7","article-title":"Reduction in overdose mortality after the opening of North America\u2019s first medically supervised safer injecting facility: a retrospective population-based study","volume":"377","author":"Marshall","year":"2011","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.amjmed.2026.07.049_bib0063","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.10077","article-title":"Fentanyl test strip use and overdose risk reduction behaviors among people who use drugs","volume":"8","author":"Vickers-Smith","year":"2025","journal-title":"Jama Netw Open"},{"key":"10.1016\/j.amjmed.2026.07.049_bib0064","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2022.109645","article-title":"Risks and overdose responses: participant characteristics from the first seven years of a national take-home naloxone program","volume":"240","author":"Ericson","year":"2022","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"10.1016\/j.amjmed.2026.07.049_bib0065","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13011-023-00533-2","article-title":"Sweden\u2019s first take-Home Naloxone program: participant characteristics, dose endpoints and predictors for overdose reversals","volume":"18","author":"Holm\u00e9n","year":"2023","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"10.1016\/j.amjmed.2026.07.049_bib0066","doi-asserted-by":"crossref","first-page":"f174","DOI":"10.1136\/bmj.f174","article-title":"Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis","volume":"346","author":"Walley","year":"2013","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.amjmed.2026.07.049_bib0067","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.40006","article-title":"Communities that HEAL intervention and mortality including polysubstance overdose deaths: a randomized clinical trial","volume":"7","author":"Freisthler","year":"2024","journal-title":"Jama Netw Open"},{"issue":"1","key":"10.1016\/j.amjmed.2026.07.049_bib0068","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2105\/AJPH.2024.307845","article-title":"Effect of the communities that HEAL intervention on overdose education and naloxone distribution: a cluster-randomized, wait-list controlled trial","volume":"115","author":"Freeman","year":"2025","journal-title":"Am J Public Health"},{"key":"10.1016\/j.amjmed.2026.07.049_bib0069","unstructured":"R. Wang. Naloxone for opioid associated out of hospital cardiac arrest (NOPACA). d oi:NCT06251609"},{"issue":"2","key":"10.1016\/j.amjmed.2026.07.049_bib0070","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.0117","article-title":"Association of take-home naloxone and opioid overdose reversals performed by patients in an opioid treatment program","volume":"3","author":"Katzman","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"5","key":"10.1016\/j.amjmed.2026.07.049_bib0071","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/add.13265","article-title":"Effectiveness of Scotland\u2019s National Naloxone Programme for reducing opioid-related deaths: a before (2006-10) versus after (2011-13) comparison","volume":"111","author":"Bird","year":"2016","journal-title":"Addict Abingdon Engl"},{"issue":"5","key":"10.1016\/j.amjmed.2026.07.049_bib0072","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1111\/add.15236","article-title":"Skin-cleaning among hospitalized people who inject drugs: a randomized controlled trial","volume":"116","author":"Stein","year":"2021","journal-title":"Addiction"},{"issue":"1","key":"10.1016\/j.amjmed.2026.07.049_bib0073","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/add.13089","article-title":"Innovative community-based educational face-to-face intervention to reduce HIV, hepatitis C virus and other blood-borne infectious risks in difficult-to-reach people who inject drugs: results from the ANRS-AERLI intervention study","volume":"111","author":"Roux","year":"2016","journal-title":"Addict Abingdon Engl"},{"key":"10.1016\/j.amjmed.2026.07.049_bib0074","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108646","article-title":"A randomized controlled trial of a brief behavioral intervention to reduce skin and soft tissue infections among people who inject drugs","volume":"221","author":"Phillips","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.amjmed.2026.07.049_bib0075","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1186\/1471-2458-8-405","article-title":"Risk factors for developing a cutaneous injection-related infection among injection drug users: a cohort study","volume":"8","author":"Lloyd-Smith","year":"2008","journal-title":"BMC Public Health"},{"issue":"6","key":"10.1016\/j.amjmed.2026.07.049_bib0076","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/ADM.0000000000000346","article-title":"Risk factors associated with skin and soft tissue infections among hospitalized people who inject drugs","volume":"11","author":"Phillips","year":"2017","journal-title":"J Addict Med"},{"issue":"3","key":"10.1016\/j.amjmed.2026.07.049_bib0077","first-page":"605","article-title":"Barriers and facilitators to primary care engagement for people who inject drugs: a systematic review","volume":"55","author":"Heidari","year":"2023","journal-title":"J Nurs Sch Publ Sigma Theta Tau Int Honor Soc Nurs"},{"issue":"2","key":"10.1016\/j.amjmed.2026.07.049_bib0078","first-page":"109","article-title":"Primary care for persons who inject drugs","volume":"99","author":"Visconti","year":"2019","journal-title":"Am Fam Physician"},{"issue":"11","key":"10.1016\/j.amjmed.2026.07.049_bib0079","doi-asserted-by":"crossref","first-page":"ofab489","DOI":"10.1093\/ofid\/ofab489","article-title":"Value of packaged testing for sexually transmitted infections for persons who inject drugs hospitalized with serious injection-related infections","volume":"8","author":"Marks","year":"2021","journal-title":"Open Forum Infect Dis"},{"issue":"12","key":"10.1016\/j.amjmed.2026.07.049_bib0080","doi-asserted-by":"crossref","first-page":"e1192","DOI":"10.1016\/S2214-109X(17)30375-3","article-title":"Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review","volume":"5","author":"Degenhardt","year":"2017","journal-title":"Lancet Glob Health"},{"issue":"Suppl 5","key":"10.1016\/j.amjmed.2026.07.049_bib0081","doi-asserted-by":"crossref","first-page":"S465","DOI":"10.1093\/infdis\/jiaa056","article-title":"The emerging intersection between injection drug use and early syphilis in nonurban areas of Missouri, 2012-2018","volume":"222","author":"Reno","year":"2020","journal-title":"J Infect Dis"},{"issue":"SUPPL. 1","key":"10.1016\/j.amjmed.2026.07.049_bib0082","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1097\/QAI.0b013e3181f9c0b6","article-title":"Infectious disease comorbidities adversely affecting substance users with HIV: hepatitis C and tuberculosis","volume":"55","author":"Friedland","year":"2010","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"10.1016\/j.amjmed.2026.07.049_bib0083","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2466-11-26","article-title":"Incidence, risk factors and mortality of tuberculosis in Danish HIV patients 1995-2007","volume":"11","author":"Taarnh\u00f8j","year":"2011","journal-title":"BMC Pulm Med"},{"issue":"2","key":"10.1016\/j.amjmed.2026.07.049_bib0084","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofab548","article-title":"Alarming tuberculosis rate among people who inject drugs in Vietnam","volume":"9","author":"Nagot","year":"2022","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"10.1016\/j.amjmed.2026.07.049_bib0085","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.drugpo.2011.03.003","article-title":"How many HIV infections are prevented by Vancouver Canada\u2019s supervised injection facility?","volume":"22","author":"Pinkerton","year":"2011","journal-title":"Int J Drug Policy"},{"issue":"9","key":"10.1016\/j.amjmed.2026.07.049_bib0086","article-title":"Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs. Cochrane Drugs and Alcohol Group, ed","volume":"2017","author":"Platt","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.amjmed.2026.07.049_bib0087","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/ije\/dyt243","article-title":"Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: a systematic review and meta-analysis","volume":"43","author":"Aspinall","year":"2014","journal-title":"Int J Epidemiol"},{"issue":"oct03 3","key":"10.1016\/j.amjmed.2026.07.049_bib0088","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.e5945","article-title":"Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis","volume":"345","author":"MacArthur","year":"2012","journal-title":"BMJ"},{"issue":"9883","key":"10.1016\/j.amjmed.2026.07.049_bib0089","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1016\/S0140-6736(13)61127-7","article-title":"Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"381","author":"Choopanya","year":"2013","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.amjmed.2026.07.049_bib0090","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1016\/S2352-3018(16)30207-7","article-title":"Factors associated with the uptake of and adherence to HIV pre-exposure prophylaxis in people who have injected drugs: an observational, open-label extension of the Bangkok Tenofovir Study","volume":"4","author":"Martin","year":"2017","journal-title":"Lancet HIV"},{"issue":"24","key":"10.1016\/j.amjmed.2026.07.049_bib0091","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1016\/j.vaccine.2015.04.019","article-title":"Hepatitis A and B among young persons who inject drugs\u2013vaccination, past, and present infection","volume":"33","author":"Collier","year":"2015","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.amjmed.2026.07.049_bib0092","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJMoa1600693","article-title":"Antiretroviral therapy for the prevention of HIV-1 transmission","volume":"375","author":"Cohen","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.amjmed.2026.07.049_bib0093","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/s41598-017-01862-6","article-title":"Impact of Hepatitis C treatment as prevention for people who inject drugs is sensitive to contact network structure","volume":"7","author":"Metzig","year":"2017","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.amjmed.2026.07.049_bib0094","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.jinf.2022.06.005","article-title":"High efficacy of glecaprevir\/pibrentasvir for HCV-infected individuals with active drug use","volume":"85","author":"Gonzalez-Serna","year":"2022","journal-title":"J Infect"},{"key":"10.1016\/j.amjmed.2026.07.049_bib0095","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.drugpo.2018.08.013","article-title":"Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: the SIMPLIFY study","volume":"62","author":"Cunningham","year":"2018","journal-title":"Int J Drug Policy"},{"issue":"9","key":"10.1016\/j.amjmed.2026.07.049_bib0096","doi-asserted-by":"crossref","first-page":"625","DOI":"10.7326\/M16-0816","article-title":"Elbasvir-Grazoprevir to treat Hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial","volume":"165","author":"Dore","year":"2016","journal-title":"Ann Intern Med"},{"issue":"8","key":"10.1016\/j.amjmed.2026.07.049_bib0097","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/jvh.13701","article-title":"Randomized clinical trial: direct-acting antivirals as treatment for hepatitis C in people who inject drugs: delivered in needle and syringe programs via directly observed therapy versus fortnightly collection","volume":"29","author":"Beer","year":"2022","journal-title":"J Viral Hepat"},{"issue":"9","key":"10.1016\/j.amjmed.2026.07.049_bib0098","doi-asserted-by":"crossref","first-page":"594","DOI":"10.7326\/M18-1715","article-title":"Intensive models of Hepatitis C care for people who inject drugs receiving opioid agonist therapy: a randomized controlled trial","volume":"170","author":"Akiyama","year":"2019","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.amjmed.2026.07.049_bib0099","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1001\/jamainternmed.2022.0170","article-title":"Accessible Hepatitis C care for people who inject drugs: a randomized clinical trial","volume":"182","author":"Eckhardt","year":"2022","journal-title":"Jama Intern Med"},{"issue":"6","key":"10.1016\/j.amjmed.2026.07.049_bib0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003653","article-title":"Integrated treatment of hepatitis C virus infection among people who inject drugs: a multicenter randomized controlled trial (INTRO-HCV)","volume":"18","author":"Fadnes","year":"2021","journal-title":"PLoS Med"},{"issue":"9","key":"10.1016\/j.amjmed.2026.07.049_bib0101","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1093\/cid\/ciz546","article-title":"Outcomes of treatment for Hepatitis C in primary care, compared to hospital-based care: a randomized, controlled trial in people who inject drugs","volume":"70","author":"Wade","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"16","key":"10.1016\/j.amjmed.2026.07.049_bib0102","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1001\/jama.2024.2452","article-title":"Integrated Hepatitis C-Opioid use disorder care through facilitated telemedicine: a randomized trial","volume":"331","author":"Talal","year":"2024","journal-title":"Jama"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934326006078?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934326006078?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:30:55Z","timestamp":1790685055000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934326006078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":102,"alternative-id":["S0002934326006078"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2026.07.049","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Guidelines for prevention and management of complications of injection drug use: A WikiGuidelines group consensus statement","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2026.07.049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}